INNATE PHARMA INVESTOR CONFERENCE CALL ON NOVEMBER 14, 2016 TO DISCUSS RECENT NEW CLINICAL DATA

Marseille, November 10, 2016
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that the Company will host a conference call for institutional investors and sell-side analysts to discuss recent clinical data on November 14, 2016.

During the conference call, the Company’s management team will discuss lirilumab and IPH4102 clinical data published at the most recent scientific meetings:

• SITC*: efficacy data for lirilumab in combination with nivolumab;
• ESMO†: safety data for lirilumab in combination with nivolumab or ipilimumab;
• 3WCCL‡: preliminary clinical data for IPH4102.

***INVESTOR CALL FOR RECENT NEW CLINICAL DATA***

The call will be held on November 14, 2016 at 8:00 am ET (2 pm CET)

Dial in numbers:
USA: +1 855 402 77 62
International: +33 (0) 1 70 77 09 34

Speakers:
Hervé Brailly, Chief Executive Officer of Innate Pharma
Nicolai Wagtmann, Chief Scientific Officer of Innate Pharma
Pierre Dodion, Chief Medical Officer of Innate Pharma
Jan B. Vermorken, Emeritus Professor of Oncology, University of Antwerp, Belgium

The slideshow of the presentation will be made available on the Company’s website 15 minutes before the call begins.
A replay will be available following the call on Innate Pharma’s website.

---

* Society for Immunotherapy of Cancer’s (SITC) 2016 Annual Meeting (November 9-13, 2016)
† European Society for Medical Oncology (ESMO) 2016 congress (October 7 – 11, 2016)
‡ Third World Congress of Cutaneous Lymphomas (3WCCL) (October 26-28, 2016)
About the latest and upcoming presentations:

**Lirilumab (anti-KIR antibody), partnered with Bristol-Myers Squibb:**

- Safety data for two Phase I studies conducted by Bristol-Myers Squibb, investigating lirilumab in combination with nivolumab or ipilimumab, respectively, in patients with advanced refractory solid tumors were presented at ESMO 2016 Congress. The combination of lirilumab and nivolumab showed no added toxicity over nivolumab monotherapy. The [poster](www.innatepharma.com) is available on Innate Pharma’s website.

- Efficacy data for the Phase I/II study conducted by Bristol-Myers Squibb, testing lirilumab in combination with nivolumab, in patients with advanced platinum refractory squamous cell carcinoma of the head and neck will be presented at the SITC 2016 Annual Meeting:
  - Presentation title: "Preliminary efficacy from a Phase I/II study of the natural killer cell-targeted antibody, lirilumab in combination with nivolumab in squamous cell carcinoma of the head and neck" (see on SITC website, poster 456)
  - Session: Late-Breaking Abstract Session II
  - Date: Saturday, November 12, 2016
  - Time: 11:15 - 11:30 a.m.
  - Presenter: Dr. Rom Leidner, Earle A. Chiles Research Institute, Providence Cancer Center
  - Location: Gaylord National Hotel & Convention Center

- Data from the Phase IB/II study conducted by Bristol-Myers Squibb, testing lirilumab in combination with azacytidine in patients with relapsed acute myeloid leukemia will be presented at the American Society of Hematology’s (ASH) 2016 Annual Meeting (December 3-6, 2016):
  - Poster title: "Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)"
  - Date: Saturday, December 3, 2016
  - Time: 5:30 p.m. – 7:30 p.m
  - Presenter: Dr Naval Daver, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
  - Location: Hall GH, San Diego Convention Center

**IPH4102 (anti-KIR3DL2 antibody):**

- Preliminary clinical data from the dose escalation part of the Phase I trial testing IPH4102 in patients with relapsed/refractory cutaneous T-cell lymphomas were presented at the 3WCCL. The [poster](www.innatepharma.com) and associated [presentation](www.innatepharma.com) are available on Innate Pharma’s website.

- Preliminary safety, exploratory and clinical activity results from the dose escalation part of the Phase I trial testing IPH4102 in patients with relapsed/refractory cutaneous T-cell lymphomas will be presented at the ASH 2016 Annual Meeting:
• Poster title: "First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results"
  • Date: Saturday, December 3, 2016
  • Time: 5:30 p.m. – 7:30 p.m.
  • Presenter: Pr Youn Kim, Hospital Saint Louis, Paris, France
  • Location: Hall GH, San Diego Convention Center

Monalizumab (anti-NKG2A antibody), partnered with AstraZeneca/Medimmune:
• Preclinical data generated in collaboration with AstraZeneca/MedImmune on the combination of NKG2A and PD1/PD-L1 checkpoint inhibitors will be presented in a poster at the SITC 2016 Annual Meeting. The poster will be available on Innate Pharma’s website.
  • Poster title: "NK, T cells and IFN-gamma are required for the anti-tumor efficacy of combination-treatment with NKG2A and PD1/PDL1 checkpoint inhibitors in preclinical models"
  • Date: Saturday, November 12, 2016
  • Time: 11:45 a.m. – 1:00 p.m. and 6:45 – 8:00 p.m.
  • Presenter: Dr. Pascale Andre, Innate Pharma
  • Location: Gaylord National Hotel & Convention Center

• Safety and first activity data for the dose-ranging part of the Phase I/II trial testing monalizumab as a single agent in patients with gynecologic malignancies, sponsored by the Canadian Cancer Trials Group, will be presented in a poster during the ENA Molecular Targets and Cancer Therapeutics symposium. The poster will also be presented in a “poster in the spotlight session”.
  • Poster title: “Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221”
  • Presenter: A. Tinker, Canadian Cancer Trials Group
  • Location: Gaylord National Hotel & Convention Center

• 2 poster sessions:
  • Session: Posters in the Spotlight session
  • Date: Wednesday, November 30, 2016
  • Time: 1:10 p.m. – 1:20 p.m.
  • Poster Session: Immunotherapy
  • Date: Wednesday, November 30, 2016
  • Time: 10:15 a.m. – 5:00 p.m.

About Innate Pharma:
Innate Pharma S.A. is a clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.
Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells.
The Company’s aim is to become a commercial stage biopharmaceutical company in the area
of immunotherapy and focused on serious unmet medical needs in cancer. Innate Pharma has pioneered the discovery and development of checkpoint inhibitors to activate the innate immune system. Innate Pharma’s innovative approach has resulted in three first-in-class, clinical-stage antibodies targeting natural killer cell receptors that may address a broad range of solid and hematological cancer indications as well as additional preclinical product candidates and technologies. Targeting receptors involved in innate immunity also creates opportunities for the Company to develop therapies for inflammatory diseases.

The Company’s expertise and understanding of natural killer cell biology have enabled it to enter into major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi.

Based in Marseille, France, Innate Pharma has more than 140 employees and is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

<table>
<thead>
<tr>
<th>ISIN code</th>
<th>FR0010331421</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ticker code</td>
<td>IPH</td>
</tr>
</tbody>
</table>

Disclaimer:
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website or on Innate Pharma’s website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma
Laure-Hélène Mercier
Director, Investor Relations
Tel.: +33 (0)4 30 30 30 87
investors@innate-pharma.com

Press Contacts
ATCG Press (France)
Marie Puvieux
Mob: +33 (0)6 10 54 36 72
presse@atcg-partners.com

Consilium Strategic Communications (ROW)
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Hendrik Thys / Cameron Standage
Tel.: +44 (0)20 3709 5700
InnatePharma@consilium-comms.com